A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Catharina Ziekenhuis Eindhoven
M.D. Anderson Cancer Center
Duke University
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
Novartis
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Compugen Ltd
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
NextCure, Inc.